Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Givinostat in Participants With Hepatic Impairment
NCT06736223Phase 1Completed
- Sponsor
- Italfarmaco
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of givinostat (3 arms), sponsored by Italfarmaco. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2025; status: completed.
02
Drugs
givinostat
Beyond the preview
Go deeper on NCT06736223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736223.